Delivery Order SPE2DB22D3010-SPE2DB26FP0RQ
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,519.62 for 120 tablets of Lynparza 100 mg on July 21, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside transaction executed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be performed...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,543.70 for 60 tablets of Lynparza 100 mg on July 30, 2025, with an ultimate completion date of August 20, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and is being fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location. The contract represents a continuation of pharmaceutical supply services under AmerisourceBergen's broader federal...
- The Defense Logistics Agency awarded a delivery order valued at $10,519.62 to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Lynparza 100 mg tablets (120-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 30, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Lynparza 150 mg tablets (120 count) valued at $31,702.80. This firm fixed-price delivery order is scheduled for completion by August 25, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency awarded a $10,519.62 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 120 tablets of Lynparza 100 mg, with an ultimate completion date of August 14, 2025. This is a non-set-aside, competitively awarded contract classified as a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The delivery location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp...
- The Defense Logistics Agency awarded a $10,567.60 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of 120-count units of Lynparza 150 mg tablets, with completion scheduled for September 8, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. Lynparza is a prescription oncology medication used in cancer treatment,...
- The Defense Logistics Agency awarded a delivery order valued at $10,567.60 to AmerisourceBergen Drug Corp for the supply of Lynparza 150 mg tablets (120-count units). This is a firm fixed price delivery order with no set-aside designation, competitively awarded to support federal medical procurement. The contract was awarded on September 2, 2025, with an ultimate completion date of September 23, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime...
- The Defense Logistics Agency awarded a $42,270.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Lynparza 150 mg tablets (120-count units) on August 12, 2025, with an ultimate completion date of September 3, 2025. This non-competitive delivery order is being fulfilled from AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $10,499.34 to AmerisourceBergen Drug Corp for 60 tablets of LYNPARZA 150 mg, a pharmaceutical product for oncology treatment. The contract, awarded on August 19, 2025, with an ultimate completion date of September 10, 2025, carries firm fixed pricing and represents a non-set-aside competitive award. Performance will be executed at the contractor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $21,135.20 to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Lynparza 150 mg tablets (120-count units). This firm fixed price, non-set-aside contract is scheduled for completion by October 17, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- SPE2DB22D3010Indefinite Delivery Contract
- SPE2DB22D3010-SPE2DB26FP0RQDelivery Order
The Defense Logistics Agency awarded a $10,567.60 firm fixed price delivery order to AmerisourceBergen Drug Corp on October 16, 2025, for the supply of Lynparza 150 mg tablets (120 count). The contract, which is non-set-aside and competitively awarded, is scheduled for completion by November 6, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen serves as a critical pharmaceutical distributor within the federal medical supply chain, fulfilling essential drug requirements for military and veteran healthcare systems. Lynparza, an oncology medication, represents part of the company's comprehensive portfolio of brand-name and generic pharmaceutical products supplied to the Defense Health Agency and other federal healthcare entities. As a major prime contractor under the DLA's pharmaceutical support framework, AmerisourceBergen demonstrates consistent capability to meet federal procurement standards through open competition across a diverse range of therapeutic medications and medical supplies.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.6k | 10/16/25 |